An international patent application has been filed by Mindset Pharma Inc. for its novel psilocybin synthesis method.
Drug discovery and development company, Mindset Pharma, which is focused on creating next-generation psychedelic medicines for treating neurological and neuropsychiatric disorders, has filed an international patent application for its novel psilocybin synthesis method.
Groundbreaking synthesis process
The patent application covers the company’s groundbreaking synthesis method for psilocybin and psilocin, which allows for faster synthesis compared to currently established methodologies. Mindset says the process is also lower cost, has milder reaction conditions, more convenient operations, has more easily obtained commercially available raw materials, as well as suitability for multi-kilogramme scale manufacturing and lower environmental impact.
Vice President of innovation at Mindset, Malik Slassi, said: “Since filing our provisional patent application in July of 2020, we have made substantial progress towards demonstrating the commercial viability of our synthesis process. Earlier this year, we engaged a leading international contract development and manufacturing organisation to complete optimisation and scale-up of the process.
“To date, significant optimisation work has been completed and we are now initiating a 100g pilot scale synthesis to be followed by a 1.0 kg batch of cGMP psilocybin using Mindset’s Synthesis Process. The large-scale cGMP synthesis batch is expected to be completed by the end of 2021.”
CEO of mindset, James Lanthier, added: “We believe that our proprietary synthesis process is likely the most cost-effective method available in the marketplace today for cGMP grade psilocybin. The process strategically complements our next-generation drug development programs and represents a significant potential market opportunity with near-term revenue potential.
“We anticipate that there will be significant demand for our cGMP psilocybin supply given the increasing number of trials and studies underway utilising psilocybin.”
